136 related articles for article (PubMed ID: 34238798)
1. Hepatic Cavernous Hemangioma Mimicking Metastasis of Midgut Neuroendocrine Neoplasia on 18F-Fluorodihydroxyphenylalanine PET/CT.
Noskovicova L; Kovacova M; Janik J; Marcinek J; Balogova S
Clin Nucl Med; 2022 Jan; 47(1):76-78. PubMed ID: 34238798
[TBL] [Abstract][Full Text] [Related]
2. Limited role of carbidopa-assisted
Imperiale A; Averous G; Helali M; Taieb D; Pessaux P; Goichot B; Addeo P; Bachellier P
Ann Nucl Med; 2019 Sep; 33(9):697-707. PubMed ID: 31214959
[TBL] [Abstract][Full Text] [Related]
3. Cavernous Hemangioma: A Potential Pitfall at Delayed 18F-FDG PET/CT Scan.
Scolozzi V; Giancipoli RG; Macciomei MC; Vigna L; Leccisotti L
Clin Nucl Med; 2021 Dec; 46(12):e584-e586. PubMed ID: 34269730
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDOPA PET/CT-Guided Radiofrequency Ablation of Liver Metastases from Neuroendocrine Tumours: Technical Note on a Preliminary Experience.
Cazzato RL; Garnon J; Ramamurthy N; Tsoumakidou G; Imperiale A; Namer IJ; Bachellier P; Caudrelier J; Rao P; Koch G; Gangi A
Cardiovasc Intervent Radiol; 2016 Sep; 39(9):1315-21. PubMed ID: 27048487
[TBL] [Abstract][Full Text] [Related]
5. Hepatic Cavernous Hemangioma Mimicking Malignancy on 18 F-FDG PET/CT Imaging.
Zhang Y; Wang P; Shi X; Jing H
Clin Nucl Med; 2023 Dec; 48(12):1122-1123. PubMed ID: 37882763
[TBL] [Abstract][Full Text] [Related]
6. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.
Imperiale A; Rust E; Gabriel S; Detour J; Goichot B; Duclos B; Kurtz JE; Bachellier P; Namer IJ; Taïeb D
J Nucl Med; 2014 Mar; 55(3):367-72. PubMed ID: 24343986
[TBL] [Abstract][Full Text] [Related]
7. The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia.
Bech PR; Martin NM; Ramachandran R; Bloom SR
Ann Clin Biochem; 2014 Jan; 51(Pt 1):8-21. PubMed ID: 23939195
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 68Ga-Dotatate PET/CT and 18F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient.
Jullien M; Reichert T; D'Anella P; Castinetti F; Barlier A; Brue T; Taieb D; Cuny T
Ann Endocrinol (Paris); 2020 Feb; 81(1):39-43. PubMed ID: 31982106
[TBL] [Abstract][Full Text] [Related]
9. Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors.
Ansquer C; Touchefeu Y; Faivre-Chauvet A; Leux C; Le Bras M; Régenet N; Fleury V; Maucherat B; Senellart H; Guyetant S; Carlier T; Scotet-Cérato E; Rauscher A; Frampas E; Kraeber-Bodéré F
Clin Nucl Med; 2021 Mar; 46(3):181-186. PubMed ID: 33315677
[TBL] [Abstract][Full Text] [Related]
10. The Added Diagnostic Value of
Addeo P; Poncet G; Goichot B; Leclerc L; Brigand C; Mutter D; Romain B; Namer IJ; Bachellier P; Imperiale A
J Gastrointest Surg; 2018 Apr; 22(4):722-730. PubMed ID: 29235002
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous (18)F-FDOPA PET/CT-guided biopsy and radiofrequency ablation of recurrent neuroendocrine hepatic metastasis: further step toward a theranostic approach.
Imperiale A; Garnon J; Bachellier P; Gangi A; Namer IJ
Clin Nucl Med; 2015 Jun; 40(6):e334-5. PubMed ID: 25706791
[TBL] [Abstract][Full Text] [Related]
12. The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Classification System With Prognostic Impact.
Hayes AR; Furtado O'Mahony L; Quigley AM; Gnanasegaran G; Caplin ME; Navalkissoor S; Toumpanakis C
Clin Nucl Med; 2022 Jan; 47(1):26-35. PubMed ID: 34874347
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation.
Bucau M; Laurent-Bellue A; Poté N; Hentic O; Cros J; Mikail N; Rebours V; Ruszniewski P; Lebtahi R; Couvelard A
Neuroendocrinology; 2018; 106(3):274-282. PubMed ID: 28803235
[TBL] [Abstract][Full Text] [Related]
14. Jejunal Cavernous Hemangioma Mimicking Malignancy With Increased Activity on 18 F-FDG PET/CT.
Huang WS; He YL; Liang J; Su YL; Xu JH
Clin Nucl Med; 2023 May; 48(5):409-410. PubMed ID: 36927765
[TBL] [Abstract][Full Text] [Related]
15. Clinical Value of 18F-fluorodihydroxyphenylalanine Positron Emission Tomography/Contrast-enhanced Computed Tomography (18F-DOPA PET/CT) in Patients with Suspected Paraganglioma.
El-Rabadi K; Weber M; Mayerhofer M; Nakuz T; Scherer T; Mitterhauser M; Dudczak R; Hacker M; Karanikas G
Anticancer Res; 2016 Aug; 36(8):4187-93. PubMed ID: 27466530
[TBL] [Abstract][Full Text] [Related]
16. An Incidental Uptake of 18F-Choline at PET/CT in Gastric Neuroendocrine Tumor.
Evangelista L; Cassarino G; Capobianco D; Povolato M; Battista S; Rensi M
Clin Nucl Med; 2021 Apr; 46(4):e238-e239. PubMed ID: 33031248
[TBL] [Abstract][Full Text] [Related]
17. Clinical Application of 18F-AlF-NOTA-Octreotide PET/CT in Combination With 18F-FDG PET/CT for Imaging Neuroendocrine Neoplasms.
Long T; Yang N; Zhou M; Chen D; Li Y; Li J; Tang Y; Liu Z; Li Z; Hu S
Clin Nucl Med; 2019 Jun; 44(6):452-458. PubMed ID: 30985413
[TBL] [Abstract][Full Text] [Related]
18. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
[TBL] [Abstract][Full Text] [Related]
19. Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.
Schiesser M; Veit-Haibach P; Muller MK; Weber M; Bauerfeind P; Hany T; Clavien PA
Br J Surg; 2010 May; 97(5):691-7. PubMed ID: 20225244
[TBL] [Abstract][Full Text] [Related]
20. Role of positron emission tomography in thyroid and neuroendocrine tumors.
Treglia G; Kroiss AS; Piccardo A; Lococo F; Santhanam P; Imperiale A
Minerva Endocrinol; 2018 Sep; 43(3):341-355. PubMed ID: 28949122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
